Researchers suggest the decline was linked to countries implementing movement restrictions, which resulted in fewer medical ...
Research and development (R&D) activities are anticipated to drive growth in the adenosine antagonists market by identifying novel therapeutic applications, such as in neurodegenerative diseases, ...
The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research.
In other news, HPV vaccine is credited for lower death rate among women under 25; psilocybin is being tested to treat health care worker burnout; and more.
Traumatic brain injury (TBI) is a leading cause of death and disability among young people in the United States and is the most devastating survivable injury in modern warfare, according to the ...
Pharmaceuticals announced updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial investigating its ...
In a comprehensive Genomic Press Interview, distinguished psychiatrist Professor Peter Falkai suggests promising new ...
ShiraTronics has commenced the pivotal RELIEV-CM2 CLINICAL Study of its implantable neuromodulation therapy, designed for ...
Tribe Clinical Research in Greenville has announced the launch of a new trial for a drug centered around Alzheimer's ...
WW International, Inc. WW stock has shown a remarkable performance in the past three months, outpacing the S&P 500 and the ...